Oral Tirzepatide — The Future of Weight Loss Pills
Ben Synth explores the unregulated world of oral tirzepatide products flooding the market in 2026. Despite no FDA-approved oral version existing, companies sell tablets claiming dual GIP/GLP-1 benefits—without clinical trials proving safety or efficacy. Ben examines why peptides resist oral delivery, contrasts these with Eli Lilly's legitimate candidate orforglipron, and warns about the gap between marketing and science. Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTV This content was created in partnership and with the help of Artificial Intelligence AI.
4 episoder
Kommentarer
0Vær den første til at kommentere
Tilmeld dig nu og bliv en del af Oral Tirzepatide — The Future of Weight Loss Pills-fællesskabet!